Y Intercept Hong Kong Ltd Acquires 270 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Y Intercept Hong Kong Ltd increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 14,950 shares of the medical research company’s stock after buying an additional 270 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in IQVIA were worth $3,543,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. MML Investors Services LLC boosted its stake in shares of IQVIA by 6.3% in the 3rd quarter. MML Investors Services LLC now owns 134,396 shares of the medical research company’s stock valued at $31,848,000 after purchasing an additional 7,980 shares in the last quarter. Tenere Capital LLC bought a new position in IQVIA in the 3rd quarter valued at approximately $14,896,000. Orion Portfolio Solutions LLC grew its stake in shares of IQVIA by 2.3% during the third quarter. Orion Portfolio Solutions LLC now owns 16,319 shares of the medical research company’s stock worth $3,867,000 after buying an additional 364 shares during the last quarter. iSAM Funds UK Ltd increased its holdings in shares of IQVIA by 28.3% during the third quarter. iSAM Funds UK Ltd now owns 2,576 shares of the medical research company’s stock worth $610,000 after buying an additional 568 shares in the last quarter. Finally, National Bank of Canada FI lifted its stake in shares of IQVIA by 245.0% in the 3rd quarter. National Bank of Canada FI now owns 181,423 shares of the medical research company’s stock valued at $42,992,000 after acquiring an additional 128,843 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Up 1.4 %

Shares of NYSE:IQV opened at $202.63 on Monday. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The business’s 50 day moving average is $215.18 and its 200 day moving average is $225.10. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The stock has a market cap of $36.78 billion, a price-to-earnings ratio of 26.59, a PEG ratio of 2.08 and a beta of 1.49.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Truist Financial lowered their target price on IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Deutsche Bank Aktiengesellschaft decreased their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Barclays cut their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Finally, Robert W. Baird lowered their price target on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a report on Friday, November 1st. Five research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $256.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.